NeuroThera Labs says US publishes MDMA-N-acylethanolamines patent application for PTSD treatment

• NeuroThera reported U.S. publication of a patent application for an MDMA and N-acylethanolamines combination targeting PTSD treatment.
• Application also covers potential use in anxiety and eating disorders, positioning the collaboration’s IP around psychedelic-derived therapeutics.
• Published filing adds to a joint portfolio of 13 published patent applications produced through the NeuroThera-Clearmind collaboration worldwide.
• Embodiments address how palmitoylethanolamide could influence MDMA dosing, side effects, potency, and the therapeutic window.
• Update follows FDA final guidance issued July 14, 2026 on clinical investigations for psychedelic drugs, including MDMA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurothera Labs Inc. published the original content used to generate this news brief via TheNewswire (Ref. ID: 202608240803TNWSWRCACNPR_____1kZaFyRRb) on August 24, 2026, and is solely responsible for the information contained therein.